JP2022520779A5 - - Google Patents

Info

Publication number
JP2022520779A5
JP2022520779A5 JP2021546842A JP2021546842A JP2022520779A5 JP 2022520779 A5 JP2022520779 A5 JP 2022520779A5 JP 2021546842 A JP2021546842 A JP 2021546842A JP 2021546842 A JP2021546842 A JP 2021546842A JP 2022520779 A5 JP2022520779 A5 JP 2022520779A5
Authority
JP
Japan
Application number
JP2021546842A
Other languages
Japanese (ja)
Other versions
JP7455852B2 (ja
JPWO2020167476A5 (https=
JP2022520779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015690 external-priority patent/WO2020167476A1/en
Publication of JP2022520779A publication Critical patent/JP2022520779A/ja
Publication of JP2022520779A5 publication Critical patent/JP2022520779A5/ja
Publication of JPWO2020167476A5 publication Critical patent/JPWO2020167476A5/ja
Application granted granted Critical
Publication of JP7455852B2 publication Critical patent/JP7455852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546842A 2019-02-15 2020-01-29 注射可能なフェノール製剤およびその使用の方法 Active JP7455852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806188P 2019-02-15 2019-02-15
US62/806,188 2019-02-15
PCT/US2020/015690 WO2020167476A1 (en) 2019-02-15 2020-01-29 Injectable phenol formulations and methods of their use

Publications (4)

Publication Number Publication Date
JP2022520779A JP2022520779A (ja) 2022-04-01
JP2022520779A5 true JP2022520779A5 (https=) 2022-11-08
JPWO2020167476A5 JPWO2020167476A5 (https=) 2022-11-08
JP7455852B2 JP7455852B2 (ja) 2024-03-26

Family

ID=72042651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546842A Active JP7455852B2 (ja) 2019-02-15 2020-01-29 注射可能なフェノール製剤およびその使用の方法

Country Status (6)

Country Link
US (3) US10959962B2 (https=)
EP (1) EP3923916A4 (https=)
JP (1) JP7455852B2 (https=)
CA (1) CA3129648A1 (https=)
MX (1) MX2021009777A (https=)
WO (1) WO2020167476A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112691091A (zh) * 2021-01-09 2021-04-23 胡宝贤 低浓度石炭酸的新应用
US20230190660A1 (en) * 2021-12-03 2023-06-22 Path Encapsulated pharmaceutical compositions, related methods of making, and related methods of treatment
WO2025235121A1 (en) * 2024-05-07 2025-11-13 Teclison, Inc. Tirapazamine compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
JPH0625056B2 (ja) 1989-06-01 1994-04-06 大幸薬品株式会社 鎮痙剤
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
JP4150772B2 (ja) * 2001-09-14 2008-09-17 独立行政法人産業技術総合研究所 シクロデキストリンを含有するフェノール重合物
JP2005538983A (ja) 2002-07-19 2005-12-22 メステックス アクチエンゲゼルシャフト 関節痛の治療のための薬剤を製造するための神経毒性物質の使用および同薬剤を適用する方法
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
US20120190750A1 (en) * 2011-01-24 2012-07-26 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
ES2784629T3 (es) * 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
JP6238190B2 (ja) * 2013-07-04 2017-11-29 公立大学法人大阪市立大学 コラーゲン産生促進用、エラスチン産生促進用および/またはケラチノサイト遊走促進用組成物
EP3024472A4 (en) 2013-07-22 2017-06-28 Kineta One, LLC Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
CN103602325B (zh) * 2013-11-18 2016-08-03 中国石油化工股份有限公司 一种延缓交联凝胶调剖剂及其制备方法
US20170209389A1 (en) 2014-07-23 2017-07-27 Landy Toth Precision chemical ablation and treatment of tissues
EP4059522A1 (en) * 2015-02-06 2022-09-21 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
WO2017180708A1 (en) * 2016-04-12 2017-10-19 Cell and Molecular Tissue Engineering, LLC Systems, methods and products for minimizing tissue reactions and tissue injury at an infusion site

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
JP2022520779A5 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)